FTPP Adipotide Peptide Research: Mechanism, Preclinical Data & Scientific Review
Shop Our Top Compounds
Adipotide FTPP Research Guide: Mechanism, Preclinical Data & Scientific Review
All compounds discussed in this article are for research purposes only and are not intended for human consumption. Nothing in this article constitutes medical advice or dosage guidance.
What Is the Adipotide Peptide?
The adipotide peptide — formally known as FTPP (Fat-Targeted Proapoptotic Peptide) and also referred to as prohibitin targeting peptide 1 — is a chimeric targeting peptide developed at the MD Anderson Cancer Center to selectively disrupt the blood supply of white adipose tissue. As a novel obesity treatment research compound, adipotide represents a first-in-class peptidomimetic that targets the vasculature of fat tissue rather than acting on appetite or metabolic pathways. This vascular targeting mechanism distinguishes it from conventional obesity treatment strategies studied in preclinical models. There is significant interest in the research and biohacking communities due to its novel approach and potential for targeted fat reduction.
Research on Adipotide has primarily focused on animal models, including primates and rodents, where it has demonstrated efficacy in reducing fat mass. The design relies on a targeting peptide domain (CKGGRAKDC) fused to a proapoptotic peptide sequence [D(KLAKLAK)2] via a glycine linker. This adipotide architecture enables the compound to home specifically to prohibitin on the adipocyte surface of vascular cells within white adipose tissue vasculature, then induce apoptosis upon internalization.
Unlike growth hormone secretagogues such as CJC-1295 and ipamorelin, which enhance natural growth hormone production to support fat metabolism, Adipotide directly induces apoptosis in fat tissue vasculature. Importantly, Adipotide selectively targets white adipose tissue while sparing brown adipose tissue, as the PHB1-ANXA2 receptor complex is present only in the vasculature of white fat, allowing for targeted fat reduction without impairing the beneficial thermogenic activity of brown fat.
How Adipotide Targets Adipose Tissue
The mechanism of action of adipotide proceeds through a defined sequence at the cellular level. Understanding how this compound operates is essential for researchers investigating obesity treatment approaches that target adipose tissue directly.
First, the CKGGRAKDC targeting peptide domain binds to prohibitin — specific proteins expressed on the surface of endothelial cells lining fat tissue blood vessels within white adipose tissue vasculature. Prohibitin ligands on the endothelial surface enable this selective homing. Once Adipotide binds to the PHB1-ANXA2 receptor complex on endothelial cells, it is internalized, triggering a cascade that leads to mitochondrial collapse and apoptosis of the endothelial cells, resulting in vascular atrophy and fat cell ischemia. After internalization, the proapoptotic sequence D(KLAKLAK)2 disrupts mitochondrial membranes, collapsing mitochondrial function and triggering programmed cell death of those vascular cells.
This process of selectively inducing apoptosis in adipose vasculature cells causes localized vascular collapse. Adipotide specifically targets the blood vessels feeding existing fat deposits, and this mechanism kills fat cells alive by depriving them of their blood supply. Deprived of their blood supply, fat cells in white fat depots undergo secondary cell death and the adipose tissue is resorbed. The process results in the destruction of blood vessels feeding white adipose tissue, leading to vascular atrophy, ischemia, and the death of fat cells alive. The effect is obesity-specific: lean subjects in preclinical studies showed minimal response, confirming the mechanism is selective for white fat tissue rich in prohibitin-expressing blood vessels.
Research by Salameh and colleagues further revealed that prohibitin interacts with annexin A2 and CD36 in a complex mediating fatty acid transport within adipose tissue. This suggests the targeting approach intersects with pathways handling extracellular fatty acids and fatty acid transport in white adipose tissue, adding another dimension to its activity at the cellular level. This approach is unique among fat loss peptides because it targets the blood vessels feeding fat cells rather than modulating metabolism, offering a direct method to kill fat cells and reduce existing fat deposits.
Preclinical Research: The Landmark Primate Obesity Study
The most pivotal study in adipotide research was published in Science Translational Medicine by Barnhart et al. (2011). This peptidomimetic targeting white fat was evaluated in spontaneously obese rhesus monkeys — among the most relevant animal models for human obesity research. Ten obese monkeys received adipotide at 0.43 mg/kg daily for 28 days, while five served as controls.
The results demonstrated significant weight loss that was specific to obese subjects, with minimal or no weight change observed in lean counterparts, indicating a targeted effect on fat tissue vasculature. Changes in body composition were measured using DEXA and MRI, allowing researchers to distinguish between fat loss and other tissue changes. Body weight decreased by 7–15% in treated animals. Total body fat measured by DEXA decreased by 38.7%, and abdominal fat volume measured by MRI showed significant reductions. These fat loss results continued for approximately three weeks after treatment ended, indicating sustained effects on white fat tissue and adipose tissue remodeling. The body mass index of treated rhesus monkeys decreased substantially compared to controls.
Metabolic testing revealed improved metabolic health, with improved insulin resistance markers alongside the fat loss. The insulin area under the curve decreased by 36.2%, and the insulinogenic index showed improved glucose tolerance — a 48.5% improvement versus worsening in controls. Researchers also observed rapid improvement in glucose regulation, with fasting glucose levels remaining normal throughout. Serum fatty acids showed decreasing trends consistent with healthy processing of mobilized white adipose tissue.
Foundational Rodent Studies on Obesity and Fat Cells
Foundational studies on Adipotide and FTPP utilized animal models, including both rodents and primates, to investigate their effects on obesity and fat tissue. The original mouse study by Kolonin MG, Saha, Chan, Pasqualini R, and Arap W, published in Nature Medicine (2004), demonstrated reversal of obesity by targeted ablation of adipose tissue. In diet-induced obese mice and genetically obese models, daily administration produced approximately 30% weight loss through selective destruction of adipose vasculature and white adipose tissue resorption. Unlike other fat reduction research approaches that promote fat metabolism or stimulate fat breakdown—such as growth hormone secretagogues like CJC-1295 and ipamorelin, which enhance natural growth hormone production to support fat metabolism—Adipotide does not directly stimulate fat breakdown or fat metabolism. Instead, it causes fat reduction by destroying the vasculature of adipose tissue, leading to apoptosis of fat cells. This obesity by targeted ablation research confirmed ablation of adipose tissue could produce meaningful fat loss without abnormal fat absorption.
A follow-up study by Kim, Woods, and Seeley (2010) in Diabetes revealed that the compound completely reversed diet-induced obesity in mice. Weight loss was primarily driven by reduced food intake, not increased energy expenditure. This fat targeted proapoptotic peptide effect was obesity-specific — cells in lean animals showed minimal response. Critically, the reduction in food intake occurred despite falling leptin levels, suggesting a potential pathway for a novel leptin-independent mechanism linking adipose vasculature disruption to satiety and appetite regulation — a mechanism not previously described in obesity models.
Obesity Treatment Research: Adipotide vs. Other Approaches
In the expanding landscape of obesity treatment research, Adipotide (FTPP) is part of a new class of fat loss peptides that utilize a vascular targeting mechanism. Unlike other fat loss peptides that primarily target hormonal or metabolic pathways, Adipotide stands apart by disrupting the blood vessels that supply white adipose tissue, leading to selective fat cell apoptosis. While GLP-1 agonists and incretin-based therapies address obesity through central appetite suppression, Adipotide represents a direct vascular approach to obesity treatment at the cellular level. Metabolic research continues to explore both vascular and hormonal approaches to obesity treatment, investigating how these interventions can improve glucose metabolism, insulin resistance, and adipose tissue reduction.
Feature | Adipotide (FTPP) | GLP-1 Agonists |
|---|---|---|
Approach | Vascular disruption of white adipose tissue (vascular targeting mechanism) | Central appetite suppression (hormonal/metabolic pathway) |
Target | Prohibitin on adipose tissue endothelial cells | GLP-1 receptors in brain/pancreas |
Fat Loss Type | Direct adipose tissue ablation via fat cells apoptosis | Caloric deficit-mediated |
Obesity Research Stage | Phase I clinical trial | FDA-approved |
Metabolic Effects | Improved insulin resistance, glucose tolerance | Improved glucose metabolism, weight loss |
Unlike nonspecific angiogenesis inhibitors that affect blood vessels systemically, the targeting peptide in Adipotide uses direct combinatorial selection to achieve ligand-directed specificity for white fat vasculature. This vascular targeting mechanism makes Adipotide unique among fat loss peptides studied for visceral fat reduction and metabolic syndrome improvement, distinguishing it from compounds that act through hormonal or metabolic pathways.
Prostate Cancer Research and Clinical Translation
Based on preclinical data, clinical trials for adipotide were initiated, specifically a Phase 1 clinical trial (NCT01262664) in 2012 evaluating Prohibitin-TP01 in cancer patients with metastatic prostate cancer and obesity as a comorbidity. However, this trial was discontinued without published results, and the reasons for discontinuation remain unclear. Notably, the initial clinical trial did not involve obese patients directly, but rather cancer patients who also had obesity. The dual-indication design reflected both the obesity treatment mechanism and hypothesized roles of white adipose tissue in cancer progression. Researchers noted that the vascular targeting approach used against fat tissue could also apply to various cancers, as the original targeting peptide technology was developed for cancer cells and tumor vasculature in oncology research.
The national academy-published research by Staquicini et al. in Proceedings of the National Academy of Sciences confirmed through vascular ligand receptor mapping in cancer patients that the annexin A2–prohibitin form receptor system exists in human white adipose tissue vasculature. This national academy of sciences publication provided critical translational evidence that the prohibitin-targeting strategy is conserved across species, supporting continued prostate cancer and obesity research.
Renal Considerations and Safety in Obesity Research
The primary dose-limiting observation in adipotide research involves dose-dependent renal toxicity, specifically affecting the proximal tubules of the kidneys. In primate studies, kidney lesions were classified as degenerative and necrotic, with severity increasing with dosage, indicating a clear dose-response relationship. Barnhart et al. reported mild creatinine elevations and glucosuria, but BUN did not rise concurrently — a pattern inconsistent with glomerular injury. Most changes resolved within 28 days. Mild dehydration was also noted in some studies, which could exacerbate kidney stress, highlighting the importance of hydration management during research involving Adipotide. These effects likely relate to the D-amino acid proapoptotic sequence interacting with renal D-amino acid oxidase. A safety study in 52 primates established substantial safety margins, with single doses up to 100-fold the therapeutic dose producing no lethality. The therapeutic potential of this compound continues to drive research into structural modifications for improved renal profiles.
Selectively Inducing Apoptosis: How Fat Cells Are Eliminated
At the cellular level, adipotide works by selectively inducing apoptosis in specific cells — the endothelial cells of fat tissue blood vessels that supply white adipose tissue. By targeting these fat tissue blood vessels, Adipotide leads to vascular atrophy and ischemia in white adipose tissue, effectively cutting off the blood supply to fat cells. The compound disrupts mitochondrial function through its amphipathic proapoptotic sequence, triggering programmed cell death. This induce apoptosis pathway differs fundamentally from metabolic obesity treatment approaches that modulate glucose metabolism or fatty acids processing.
The process destroys blood vessels supplying white fat, causing fat cells to lose their blood supply and undergo secondary apoptosis. Published research showed significant reductions in both subcutaneous and visceral fat, with rapid weight loss observed in treated subjects. The improved glucose tolerance and the vascular apoptosis effects in fat tissue demonstrated that this obesity treatment produces metabolic benefits beyond simple fat loss — including changes in glucose levels, glucose regulation, and overall body weight improvement consistent with meaningful obesity reduction in preclinical models.
Fat Loss and Metabolic Health
Adipotide-FTPP, known as a fat targeted proapoptotic peptide, has emerged as a compelling focus in fat loss and metabolic health research. Unlike traditional fat reduction strategies that manipulate hormonal or metabolic pathways, Adipotide-FTPP operates by directly targeting the blood vessels that nourish white adipose tissue. By binding to specific markers on the endothelial cells of these vessels, the peptide initiates programmed cell death, effectively severing the blood supply to fat cells. This targeted ablation leads to rapid fat loss, as the deprived fat cells in white adipose tissue are resorbed by the body.
The impact of this mechanism was most notably demonstrated in studies involving obese rhesus monkeys, where researchers observed significant reductions in body weight and marked improvements in insulin resistance. These findings underscore the peptide’s ability to induce substantial fat reduction without affecting other tissues, setting it apart from conventional approaches. By focusing on the vasculature of adipose tissue, Adipotide-FTPP offers a novel pathway for fat loss that holds promise for advancing obesity research and improving metabolic health outcomes.
Metabolic Benefits
The metabolic benefits of Adipotide-FTPP extend well beyond its capacity for significant fat loss. Animal studies published in Science Translational Medicine and Nature Medicine have shown that this peptide not only reduces overall fat mass but also enhances insulin sensitivity and optimizes glucose metabolism. By selectively targeting and diminishing visceral fat—a key driver of metabolic dysfunction—Adipotide-FTPP addresses one of the most challenging aspects of obesity-related disease.
Research indicates that treated subjects experience improved insulin resistance, a critical factor in the prevention and management of type 2 diabetes. The reduction in visceral fat further contributes to better overall metabolic health, as this fat depot is closely linked to adverse health outcomes. These multifaceted metabolic improvements position Adipotide-FTPP as a promising candidate in the ongoing search for effective interventions against obesity and its associated metabolic disorders.
Frequently Asked Questions
What is FTPP adipotide and how does its mechanism of action work?
FTPP adipotide is a fat targeted proapoptotic peptide (FTPP) that uses a targeting peptide domain to bind prohibitin on endothelial cells in white adipose tissue. Its mechanism of action involves inducing apoptosis in adipose vasculature cells, causing vascular collapse in white fat tissue depots. This targeted approach to obesity results in fat loss through adipose tissue resorption rather than appetite suppression.
What did research show about adipotide and obesity in obese monkeys?
In the landmark study with obese rhesus monkeys, adipotide produced 7–15% body weight reduction, 38.7% decrease in total body fat, and rapid improvement in insulin resistance and glucose tolerance. The research demonstrated that this obesity treatment approach specifically targets white adipose tissue while preserving other tissues. Published in Science Translational Medicine, the study is considered pivotal for obesity research and confirmed adipotide in a relevant primate model.
How does adipotide research relate to cancer research?
Adipotide technology originated from oncology research into cancer cells and tumor vasculature. A Phase I clinical trial evaluated adipotide in cancer patients with prostate cancer and obesity. The JCI Insight publication by Salameh et al. further explored how prohibitin and annexin A2 regulate fatty acid transport in adipose tissue, connecting obesity and cancer biology at the molecular level.
For research updates, you may receive marketing communications by providing a valid phone number or email. These marketing communications relate exclusively to research compound availability and scientific publications.
Explore the Iron Peak Peptides catalog for research-grade compounds including Adipotide (FTPP). Visit our Peptide Glossary for additional scientific context on targeting peptide research.
Research Disclaimer
All compounds discussed in this article are intended for research purposes only and are not for human consumption. FTPP (Adipotide) is sold strictly as a research chemical. All data discussed derives from published preclinical and early clinical research. Nothing in this article should be interpreted as medical advice or obesity treatment recommendations. Researchers must comply with all applicable institutional, local, and federal regulations governing the purchase and use of research peptides.
Conclusion
In summary, Adipotide-FTPP represents a groundbreaking advancement in obesity research, offering a unique approach to fat loss and metabolic health. By specifically targeting the blood vessels supplying white adipose tissue, this experimental compound enables rapid fat loss, improved insulin sensitivity, and significant reductions in visceral fat. Its mechanism stands apart from traditional therapies, focusing on the vasculature of adipose tissue rather than relying on hormonal or metabolic pathways.
While the results from preclinical and early clinical research are promising, it is important to recognize that Adipotide-FTPP remains an experimental compound. Continued research is essential to fully elucidate its effects, safety profile, and potential applications in both obesity and cancer research. As scientific interest in targeted fat reduction and metabolic health grows, Adipotide-FTPP is poised to remain at the forefront of innovation in the field, driving new discoveries and potential therapies for obesity-related diseases.
🔬 Explore Research Peptides
- Thymosin Alpha-1 10mg — $65.00
- Adipotide 5mg — $69.00
- Tesamorelin + Ipamorelin 11mg/6mg (17mg) — $89.00
- Kisspeptin-10 10mg — $59.99
